tradingkey.logo
tradingkey.logo

MaxCyte Inc

MXCT
1.630USD
+0.130+8.67%
終値 12/22, 16:00ET15分遅れの株価
173.83M時価総額
損失額直近12ヶ月PER

MaxCyte Inc

1.630
+0.130+8.67%

詳細情報 MaxCyte Inc 企業名

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

MaxCyte Incの企業情報

企業コードMXCT
会社名MaxCyte Inc
上場日Mar 29, 2016
最高経営責任者「CEO」Masoud (Maher)
従業員数114
証券種類Ordinary Share
決算期末Mar 29
本社所在地9713 Key West Avenue,
都市ROCKVILLE
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号20850
電話番号13015175556
ウェブサイトhttps://www.maxcyte.com/
企業コードMXCT
上場日Mar 29, 2016
最高経営責任者「CEO」Masoud (Maher)

MaxCyte Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+86.70%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
事業別USD
会社名
収益
比率
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%

株主

更新時刻: Mon, Dec 1
更新時刻: Mon, Dec 1
株主統計
種類
株主統計
株主統計
比率
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
他の
66.67%
株主統計
株主統計
比率
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
他の
66.67%
種類
株主統計
比率
Investment Advisor/Hedge Fund
24.33%
Investment Advisor
22.61%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
他の
23.16%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Cadian Capital Management LP
8.91M
8.36%
-1.11M
-11.10%
Jun 30, 2025
Mirabella Financial Services LLP
6.60M
6.19%
+2.90M
+78.38%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
7.7%
+793.69K
+10.70%
Jun 30, 2025
The Vanguard Group, Inc.
5.60M
5.25%
+36.02K
+0.65%
Jun 30, 2025
River Global Investors LLP
3.25M
3.05%
+1.19M
+57.73%
Dec 31, 2024
Vitruvian Partners LLP
5.04M
4.73%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
4.23M
3.97%
+795.36K
+23.12%
Jun 30, 2025
Mudita Advisors LLP
3.37M
3.16%
+42.25K
+1.27%
Jun 30, 2025
AXA Investment Managers UK Ltd.
2.20M
2.07%
+1.22M
+123.16%
Jun 30, 2025
AXA Investment Managers Paris
2.20M
2.07%
--
--
Jul 31, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
詳細を見る
Invesco NASDAQ Future Gen 200 ETF
比率0.6%
iShares Micro-Cap ETF
比率0.03%
Invesco Nasdaq Biotechnology ETF
比率0.02%
Avantis US Small Cap Equity ETF
比率0.02%
ProShares Ultra Nasdaq Biotechnology
比率0.02%
iShares Russell 2000 Value ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
iShares Biotechnology ETF
比率0.01%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

MaxCyte Incの上位5名の株主は誰ですか?

MaxCyte Incの上位5名の株主は以下のとおりです。
Cadian Capital Management LPは8.91M株を保有しており、これは全体の8.36%に相当します。
Mirabella Financial Services LLPは6.60M株を保有しており、これは全体の6.19%に相当します。
BlackRock Institutional Trust Company, N.A.は8.21M株を保有しており、これは全体の7.70%に相当します。
The Vanguard Group, Inc.は5.60M株を保有しており、これは全体の5.25%に相当します。
River Global Investors LLPは3.25M株を保有しており、これは全体の3.05%に相当します。

MaxCyte Incの株主タイプ上位3種は何ですか?

MaxCyte Incの株主タイプ上位3種は、
Cadian Capital Management LP
Mirabella Financial Services LLP
BlackRock Institutional Trust Company, N.A.

MaxCyte Inc(MXCT)の株式を保有している機関の数はいくつですか?

2025Q3時点で、MaxCyte Incの株式を保有している機関は287社あり、保有株式の総市場価値は約82.96Mで、全体の77.85%を占めています。2025Q2と比較して、機関の持ち株は3.93%増加しています。

MaxCyte Incの最大の収益源は何ですか?

FY2025Q2において、Product sales部門がMaxCyte Incにとって最大の収益を生み出しており、その金額は5.27Mで、全収益の61.94%を占めています。
KeyAI